Lupimet Mechanism of Action

Pharmacokinetics: Glimepiride: Single oral dose of Glimepiride, 1 and 8 mg results in a Cmax of 103.2 and 550.8 μg/L. The Tmax is found to be between 2.4 to 3.75 hours in Type II diabetic patients. The volume of distribution is low as the plasma protein binding is very high (99%). Accumulation does not occur after multiple doses of Glimepiride. Glimepiride is metabolized mainly in the liver to active metabolites 37-52% of Glimepiride is found in urine as metabolites within 48 hours. T½ is about 5 hours after the first dose, which increases up to 9.2 hours after multiple doses.
Metformin: Following a single oral dose of Metformin HCl Extended Release, Cmax is achieved with a median value of 7 hours and a range of 4 to 8 hours. Metformin has an absolute oral bioavailability of 50 to 60%. Although the extent of Metformin absorption (as measured by AUC) from the extended release Metformin tablet increased by approximately 50% when given with food, there was no effect of food on Cmax and Tmax. Both high and low fat meals had the same effects on the pharmacokinetics of extended release Metformin. Following absorption, Metformin is rapidly distributed and does not bind to plasma proteins. It does not undergo hepatic metabolism or biliary excretion. The drug undergoes renal excretion and has a plasma elimination half life of 6.2 hours after oral administration. In patients with decreased renal functions, the plasma and blood half life of Metformin is prolonged and the renal clearance is decreased in proportion to the decrease in creatinine clearance.